Wedbush lowers its rating on Meridian Bioscience VIVO due to a high probability of a significant miss and guidance reset from the company. Price target is lowered to $14 rom $16 a share.
Wedbush says, "VIVO's recent fiscal 1Q12 results missed by ~7% ($3 MM and $0.02) yet 2012 guidance was reiterated. VIVO is essentially implying 11% sequential top-line growth for the next three quarters. Given the company's poor 24-month growth track record, murky situation in EU and worsening competitive situation in the small hospital
segment, we believe hiccups are probable in 2012 and share price appreciation is
unlikely."
VIVO closes at $18.58 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in